Neuroprotection of Retinal Ganglion Cells by VEGF-B
About the Research Project
Program
Award Type
Standard
Award Amount
$88,920
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
G2007005
Acknowledgement
Goals
We hypothesize that VEGF-B may have a neuroprotective effect on the retinal ganglion cells. To test this hypothesis, we will use multiple approaches and methods, including both normal and VEGF-B transgenic mice, both protein and gene transfer, both gain and loss of function analysis, to investigate the neuroprotective effect of VEGF-B on retinal ganglion cells in vivo.
Summary
Glaucoma is the most prevalent form of adult optic neuropathy characterized by the degeneration and death of the retinal ganglion cells (RGCs). Molecules with neuroprotective effect on the endangered RGCs are therefore much desired to preserve and rescue the RGCs and thus the vision of glaucoma patients. This research proposal is therefore designed to test in vivo the neuroprotective effect of one such candidate molecule, the vascular endothelium growth factor B (VEGF-B), and to further characterize the molecular and cellular mechanisms underlying. VEGF-B has been shown to be a critical neuroprotective factor in the brain. Our current work has shown that VEGF-B may play important roles in the retina. The outcome of this study may lead to possibilities of novel therapy for glaucoma patients and more insight into the course of glaucoma.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute